Stemline Therapeutics

• NCT07634601

  Collaborator, Phase 2, Not yet recruiting, 50 people, 9 Jun 2026

• NCT07148180

  Collaborator, Phase 1/2, Recruiting, 31 people, 29 Aug 2025

• NCT07007052

  Collaborator, Phase 2, Recruiting, 33 people, 5 Jun 2025

• NCT06492616

  Phase 3, Recruiting, 4,220 people, 9 Jul 2024

• NCT06456463

  Phase 2, Active, not recruiting, 85 people, 13 Jun 2024

• NCT06382948

  Collaborator, Phase 3, Recruiting, 300 people, 24 Apr 2024

• NCT05563220

  Phase 1/2, Active, not recruiting, 435 people, 3 Oct 2022

• NCT05442216

  Collaborator, Phase 2, Recruiting, 53 people, 1 Jul 2022

• NCT03778931

  Phase 3, Completed, 478 people, 19 Dec 2018

• NCT03113643

  Collaborator, Phase 1, Recruiting, 72 people, 13 Apr 2017

• Modulation of the clonal burden in patients with lower-risk myelodysplastic neoplasms treated with imetelstat

  Consulting or advice, Fees or honoraria, Board or leadership role, 12 Jan 2026

Sources: pubmed.ncbi.nlm.nih.gov